Get the Stockscreener App
0.3559
0.99%
0.0035
After Hours:
.37
0.0141
+3.96%
Cyclacel Pharmaceuticals Inc stock is traded at $0.3559, with a volume of 244.27K.
It is up +0.99% in the last 24 hours and down -3.21% over the past month.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
See More
Previous Close:
$0.3524
Open:
$0.365
24h Volume:
244.27K
Relative Volume:
0.07
Market Cap:
$2.24M
Revenue:
$74,000
Net Income/Loss:
$-13.43M
P/E Ratio:
-0.0379
EPS:
-9.4
Net Cash Flow:
$-10.54M
1W Performance:
-15.24%
1M Performance:
-3.21%
6M Performance:
-79.66%
1Y Performance:
-82.97%
1-Day Range:
$0.3451
$0.378
1-Week Range:
$0.3411
$0.4199
52-Week Range:
$0.3101
$4.00
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
Name
Cyclacel Pharmaceuticals Inc
Sector
Industry
Phone
908-517-7330
Address
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Compare CYCC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYCC
Cyclacel Pharmaceuticals Inc
|
0.3559 | 2.24M | 74,000 | -13.43M | -10.54M | -9.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Apr-27-20 | Resumed | ROTH Capital | Buy |
| Sep-07-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-15 | Initiated | H.C. Wainwright | Buy |
| Feb-04-10 | Initiated | Roth Capital | Buy |
| Oct-28-09 | Initiated | Merriman | Buy |
| Aug-12-08 | Initiated | Piper Jaffray | Buy |
| Mar-12-08 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-12-08 | Reiterated | Collins Stewart | Buy |
| Mar-12-08 | Reiterated | Needham & Co | Buy |
| Nov-27-07 | Reiterated | Cantor Fitzgerald | Buy |
| Aug-10-07 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-04-07 | Reiterated | Needham & Co | Buy |
| Apr-23-07 | Initiated | Lazard Capital | Buy |
| Apr-10-07 | Initiated | Cantor Fitzgerald | Buy |
View All
Cyclacel Pharmaceuticals Inc Stock (CYCC) Latest News
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated at StockNews.com - Defense World
All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy - MSN
Cyclacel Pharmaceuticals Corrects Inadvertent Error in Securities Purchase Agreement - Defense World
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com - Defense World
Cyclacel Pharmaceuticals Announces Agreement for $3.1 Million Investment by David Lazar as Interim CEO - Defense World
Cyclacel Pharmaceuticals Restructures Leadership and Financial Strategy - TipRanks
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar - citybiz
Stock market news: Nauticus Robotics gained 93.71% while N2OFF rose by 128.03% during mid day trading - Business Upturn
Cyclacel Pharmaceuticals, Inc. Announces Chief Executive Officer Changes - Marketscreener.com
Why Cyclacel Pharmaceuticals (CYCC) Stock Is Skyrocketing - Benzinga
Cyclacel Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
Dow Jumps Over 100 Points; ISM Manufacturing PMI Increases In December - Benzinga
David Lazar acquires Cyclacel Pharmaceuticals preferred stock, becomes interim CEO; stock jumps - Seeking Alpha
Cyclacel Pharmaceuticals Secures $3.1M Investment, Names David Lazar as Interim CEO Amid Restructuring - StockTitan
Royal Bank of Canada (RY-T) QuotePress Release - The Globe and Mail
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
Trend Tracker for (CYCCP) - Stock Traders Daily
Cyclacel stock plunges to 52-week low, hits $0.32 - Investing.com India
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.com - Defense World
Stock Watch: A Biotech Holiday Horror Story - Citeline News & Insights
Cyclacel Pharmaceuticals Faces Potential Delisting from Nasdaq Stock Market Due to Minimum Bid Price Noncompliance - Defense World
Trading (CYCCP) With Integrated Risk Controls - Stock Traders Daily
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs - The Manila Times
Cyclacel Pharmaceuticals Exploring Alternatives, Cuts Costs to Preserve Cash - MarketWatch
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of - EIN News
Cyclacel Pharmaceuticals Seeks Urgent Strategic Options Amid Nasdaq Delisting Risk - StockTitan
Li Auto Inc ADR (LI-Q) QuotePress Release - The Globe and Mail
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $2.062112 million in funding - Marketscreener.com
Cyclacel Pharmaceuticals, Inc. announced that it has received $2.062112 million in funding - Marketscreener.com
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cyclacel stock plunges to 52-week low of $0.32 amid market challenges By Investing.com - Investing.com South Africa
Cyclacel stock plunges to 52-week low of $0.32 amid market challenges - Investing.com
Cyclacel Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds - The Manila Times
Armistice Capital, LLC Increases Stake in Cyclacel Pharmaceutica - GuruFocus.com
Cyclacel Pharmaceuticals Raises $2.1M Through Warrant Exercise at $0.415 Per Share | CYCC Stock News - StockTitan
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss - MSN
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds - The Manila Times
Cyclacel stock plunges to 52-week low of $0.37 amid market challenges - Investing.com Canada
Cyclacel Pharmaceuticals Raises $2.1M Through Warrant Exercise Deal at $0.415 Per Share | CYCC Stock News - StockTitan
Cyclacel Pharmaceuticals appoints new auditor By Investing.com - Investing.com Australia
Cyclacel Pharmaceuticals appoints new auditor - Investing.com India
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update - The Manila Times
Cyclacel Faces Delisting Risk Despite 67% Lower Q3 Loss; Cash Concerns Mount | CYCC Stock News - StockTitan
(CYCCP) Technical Pivots with Risk Controls - Stock Traders Daily
Acute Myeloid Leukemia (AML) Treatment Market in APAC to Grow by USD 305.8 Million from 2024-2028, Driven by High Incidence and AI-Driven Market TransformationTechnavio - The Malaysian Reserve
A Data-Based Look At Cyclacel Pharmaceuticals Inc (CYCC) - Stocks Register
Cyclacel stock plunges to 52-week low at $0.6 amid market challenges - Investing.com
Cyclacel Pharmaceuticals Inc Stock (CYCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):